MedWatch

Novo management sees lower risk and opportunity

According to the Novo Nordisk management team, the company’s businesses are less exposed to risks now than in the beginning of 2017 and this has led to a narrowing of its full year guidance. But at the same time, the opportunities for this year have decreased, according to CEO Lars Fruergaard Jørgensen.

Kommende adm. direktør for Novo Nordisk, september 2016.
Photo: /ritzau/Melissa Kühn Hjerrild

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles